मूलभूत आँकड़े
| LEI | 4YV9Y5M8S0BRK1RP0397 |
| CIK | 310158 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Schering Plough Corp
SEC Filings (Chronological Order)
यह पृष्ठ SEC फाइलिंग की एक पूरी, कालानुक्रमिक सूची प्रदान करता है, ओनरशिप फाइलिंग को छोड़कर, जो हम अन्यत्र प्रदान करते हैं।
| September 4, 2025 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-278066 Prospectus Supplement (To Prospectus dated May 14, 2024) $6,000,000,000 Merck & Co., Inc., Rahway, N.J., USA $500,000,000 Floating Rate Notes due 2027 $750,000,000 3.850% Notes due 2027 $750,000,000 4.150% Notes due 2030 $1,000,000,000 4.550% Notes due 2032 $1,750,000,000 4.950% Notes due 2035 $1,250,000,000 5.700% Notes due 2055 We are |
|
| September 4, 2025 |
Calculation of Filing Fee Tables S-3 Merck & Co., Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial E |
|
| September 3, 2025 |
Issuer Free Writing Prospectus Filed under Rule 433 Registration Statement No. 333-278066 Pricing Term Sheet Merck & Co., Inc. September 2, 2025 Floating Rate Notes due 2027 3.850% Notes due 2027 4.150% Notes due 2030 4.550% Notes due 2032 4.950% Notes due 2035 5.700% Notes due 2055 The 3.850% Notes due 2027, 4.150% Notes due 2030, 4.550% Notes due 2032, 4.950% Notes due 2035 and 5.700% Notes due |
|
| September 2, 2025 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-278066 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is unlawful or not permitted. Su |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-6571 Merck & Co., Inc. (Exact nam |
|
| July 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 29, 2025 (July 25, 2025) Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commission File |
|
| July 29, 2025 |
Exhibit 99.1 - 1 - News Release Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2025 Financial Results - Total Worldwide Sales Were $15.8 Billion, a Decrease of 2% From Second Quarter 2024 Both Nominally and Excluding the Impact of Foreign Exchange o KEYTRUDA Sales Were $8.0 Billion, Growth of 9% Both Nominally and Excluding the Impact of Foreign Exchange o WINREVAIR Sales Were $336 |
|
| July 29, 2025 |
Exhibit 99.2 MERCK & CO., INC., RAHWAY, N.J., USA CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a 2025 2024 % Change 1Q 2Q June YTD 1Q 2Q June YTD 3Q 4Q Full Year 2Q June YTD Sales $ 15,529 $ 15,806 $ 31,335 $ 15,775 $ 16,112 $ 31,887 $ 16,657 $ 15,624 $ 64,168 -2 % -2 % Costs, Expenses and Other Cost of sales 3,419 3,557 6,976 3,540 3,7 |
|
| June 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS Pursuant to Section 15(d) of the Securities Exchange Act of 1934 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 1 |
|
| June 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS Pursuant to Section 15(d) of the Securities Exchange Act of 1934 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 1 |
|
| June 27, 2025 |
11-K 1 a11-kmerckussavingsplanye.htm 11-K MERCK US SAVINGS PLAN UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS Pursuant to Section 15(d) of the Securities Exchange Act of 1934 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ende |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD Specialized Disclosure Report Merck & Co., Inc. (Exact Name of Registrant as Specified in Its Charter) New Jersey 1-6571 (State or other jurisdiction of incorporation or organization) (Commission File Number) 126 East Lincoln Avenue, Rahway, NJ 07065 (Address of principal executive offices) (Zip Code) Jennifer Zachary |
|
| May 30, 2025 |
Exhibit 1.01 CONFLICT MINERALS REPORT FOR CALENDAR YEAR 2024 Part I: Introduction This document constitutes Merck & Co., Inc.’s Conflict Minerals Report (the “Report” or “CMR”) for the year ended December 31, 2024. We have prepared this Report and are issuing it in accordance with the requirements of Rule 13p-1 under the Securities Exchange Act of 1934, as amended, and in connection with Merck & C |
|
| May 29, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 29, 2025 (May 27, 2025) Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commission File N |
|
| May 7, 2025 |
United States Securities and Exchange Commission Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION Pursuant to Rule 14a-103 Name of the Registrant: Merck & Co., Inc. Name of persons relying on exemption: National Legal and Policy Center Address of persons relying on exemption: 107 Park Washington Court, Falls Church, VA 22046 Written materials are submitted pursuant to Rule 14a-6(g) (1) promulg |
|
| May 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-6571 Merck & Co., Inc. (Exact na |
|
| April 24, 2025 |
Notice of Exempt Solicitation Pursuant to Rule 14a-103 Notice of Exempt Solicitation Pursuant to Rule 14a-103 Name of Registrant: Merck & Co. |
|
| April 24, 2025 |
Merck Announces First-Quarter 2025 Financial Results Exhibit 99.1 News Release Merck Announces First-Quarter 2025 Financial Results - Total Worldwide Sales Were $15.5 Billion, a Decrease of 2% From First Quarter 2024; Excluding the Impact of Foreign Exchange, Sales Grew 1% o KEYTRUDA Sales Grew 4% to $7.2 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 6% o WINREVAIR Sales Were $280 Million o Animal Health Sales Grew 5% to $1.6 Billion |
|
| April 24, 2025 |
Exhibit 99.2 MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a 2025 2024 % Change 1Q 1Q 2Q 3Q 4Q Full Year 1Q Sales $ 15,529 $ 15,775 $ 16,112 $ 16,657 $ 15,624 $ 64,168 -2 % Costs, Expenses and Other Cost of sales 3,419 3,540 3,745 4,080 3,828 15,193 -3 % Selling, general and administrative 2,552 2,483 2,739 2,731 2,864 |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 24, 2025 (April 24, 2025) Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commission Fi |
|
| April 16, 2025 |
126 East Lincoln Avenue P.O. Box 2000 Rahway, NJ 07065 T: 908-740-4000 E: [email protected] merck.com April 16, 2025 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 RE: Merck & Co., Inc. Form 10-K for the Fiscal Year Ended December 31, 2024 File No. 1-06571 Ladies and Gentlemen: Merck & |
|
| April 14, 2025 |
Notice of Exempt Solicitation NAME OF REGISTRANT: Merck & Co., Inc NAME OF PERSON RELYING ON EXEMPTION: Mercy Investment Services ADDRESS OF PERSON RELYING ON EXEMPTION: 2039 N Geyer Rd, Frontenac, MO 63131 Written materials are submitted pursuant to Rule 14a-6(g)(1) promulgated under the Securities Exchange Act of 1934. The soliciting person does not beneficially own more than $5 million of the c |
|
| April 9, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definit |
|
| April 9, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2 |
|
| February 25, 2025 |
Corporate Policy 11.0: Insider Trading Exhibit 19 What You Need to Know As employees of Merck & Co., Inc., Rahway, NJ, USA known as MSD outside the United States and Canada (our Company), we, our family members and related persons do not trade in our Company securities – or tip others to do so – based on material, non-public (or “inside”) information. We recognize that insider trading undermines i |
|
| February 25, 2025 |
Certified Resolution of Board of Directors Exhibit 24.2 I, Kelly Grez, Corporate Secretary of Merck & Co., Inc. (the “Company”), a corporation duly organized and existing under the laws of the State of New Jersey, do hereby certify that the following is a true copy of a resolution adopted by unanimous written consent of the Board of Directors of the Company on February 25, 2025 in accordance with the provisions of the By-Laws of the Compan |
|
| February 25, 2025 |
Merck & Co., Inc. Executive Incentive Plan (as amended and restated effective January 1, 2025) I.INTRODUCTION The Plan is designed to provide for awards to selected salaried employees in managerial or other important positions, who, individually or as members of a group, contribute in a substantial degree to the success of the Company, and who are in a position to have a direct and significant impact on the growth and success of the Company, thus affording to them a means of participating i |
|
| February 25, 2025 |
2024 Performance Share Unit terms for grants under the Merck & Co., Inc. 2019 Incentive Stock Plan GLOBAL TERMS AND CONDITIONS 2024 PERFORMANCE SHARE UNIT GRANTS UNDER THE MERCK & CO. |
|
| February 25, 2025 |
GLOBAL TERMS AND CONDITIONS 2024 NON-QUALIFIED STOCK OPTION (NQSO) GRANTS UNDER THE MERCK & CO. |
|
| February 25, 2025 |
GLOBAL TERMS AND CONDITIONS 2024 RETENTION RESTRICTED STOCK UNIT GRANT FOR RICHARD DELUCA UNDER THE MERCK & CO. |
|
| February 25, 2025 |
Exhibit 4.11 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of February 25, 2025, Merck & Co., Inc. had eight classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: (i) Common Stock, (ii), 1.875% Notes due 2026, (iii) 3.250% Notes due 2032, (iv) 2.500% Notes due 2034, (v) 1.375% N |
|
| February 25, 2025 |
MERCK & CO. INC. U.S. SEPARATION BENEFITS PLAN Amended and Restated as of January 1, 2019 MERCK & CO., INC., U.S. SEPARATION BENEFITS PLAN SECTION 1 PREAMBLE Merck Sharp & Dohme Corp. established the MSD Separation Benefits Plan (the "MSD Plan"), as amended from time to time, to provide benefits to eligible non-union employees whose employment with Merck Sharp & Dohme Corp. or a participating whol |
|
| February 25, 2025 |
As filed with the Securities and Exchange Commission on February 25, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| February 25, 2025 |
GLOBAL TERMS AND CONDITIONS 2024 SIGN-ON EQUITY GRANT OF RESTRICTED STOCK UNIT GRANTS FOR BETTY LARSON UNDER THE MERCK & CO. |
|
| February 25, 2025 |
Offer Letter between Merck & Co., Inc. and Betty Larson, dated January 16, 2024 Confidential January 16, 2024 Betty Larson 159 Abingdon Avenue Kenilworth, IL 60043 Dear Betty, It is my pleasure to offer you a position with Merck Sharp & Dohme LLC (“MSD” or the “Company”), a wholly-owned subsidiary of Merck & Co. |
|
| February 25, 2025 |
Exhibit 24.1 POWER OF ATTORNEY Each of the undersigned does hereby appoint JENNIFER ZACHARY as his/her true and lawful attorney to execute on behalf of the undersigned (whether on behalf of the Company, or as an officer or director thereof, or by attesting the seal of the Company, or otherwise) the Annual Report on Form 10-K of Merck & Co., Inc. for the fiscal year ended December 31, 2024 under th |
|
| February 25, 2025 |
GLOBAL TERMS AND CONDITIONS 2024 RESTRICTED STOCK UNIT GRANTS UNDER THE MERCK & CO. |
|
| February 25, 2025 |
Subsidiaries of Merck & Co., Inc. Exhibit 21 - MERCK & CO., INC. SUBSIDIARIES changes as 12/31/2024 The following is a list of subsidiaries of the Company, doing business under the name stated. Name Country or State of Incorporation 7728026 Canada Inc. Canada Abceutics, Inc. Delaware Abmaxis Inc. Delaware Acceleron Pharma Inc. Delaware Afferent Pharmaceuticals, Inc. Delaware Agrident GmbH Germany Allflex Argentina S.A. Argentina A |
|
| February 4, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 4, 2025 (February 4, 2025) Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commissio |
|
| February 4, 2025 |
Merck Announces Fourth-Quarter and Full-Year 2024 Financial Results Exhibit 99.1 News Release Merck Announces Fourth-Quarter and Full-Year 2024 Financial Results - Fourth-Quarter Worldwide Sales Were $15.6 Billion, an Increase of 7% From Fourth Quarter 2023; Excluding the Impact of Foreign Exchange, Growth Was 9% - Fourth-Quarter GAAP EPS Was $1.48; Non-GAAP EPS Was $1.72; GAAP and Non-GAAP EPS Include a Charge of $0.23 per Share Related to Certain Business Develo |
|
| February 4, 2025 |
Exhibit 99.2 MERCK & CO., INC. CONSOLIDATED STATEMENT OF OPERATIONS - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a 2024 2023 % Change 1Q 2Q 3Q 4Q Full Year 1Q 2Q 3Q 4Q Full Year 4Q Full Year Sales $ 15,775 $ 16,112 $ 16,657 $ 15,624 $ 64,168 $ 14,487 $ 15,035 $ 15,962 $ 14,630 $ 60,115 7 % 7 % Costs, Expenses and Other Cost of sales 3,540 3,745 4,080 3,828 15,193 3,926 |
|
| December 23, 2024 |
Joint Filing Agreement Pursuant to Rule 13d-1 Exhibit 99.1 Joint Filing Agreement Pursuant to Rule 13d-1 This agreement is made pursuant to Rule 13d-l(k)(1) under the Securities and Exchange Act of 1934, as amended (the “Act”) by and among the parties listed below, each referenced to herein as a “Joint Filer.” The Joint Filers agree that a statement of beneficial ownership as required by Sections 13(g) or 13(d) of the Act and the Rules thereu |
|
| November 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 22, 2024 (November 19, 2024) Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commiss |
|
| November 22, 2024 |
Exhibit 3.1 By-Laws OF MERCK & CO., INC. Effective as of November 19, 2024 By-Laws OF Merck & Co., Inc. A R T I C L E I. SHAREHOLDERS. SECTION 1. Annual Meeting. A meeting of the shareholders of Merck & Co., Inc. (hereinafter referred to as the “Company”) shall be held at such places as may from time to time be designated by the Board of Directors and stated in the notice of the meeting for the pu |
|
| November 22, 2024 |
Surendralal Karsanbhai Elected to Merck Board of Directors Exhibit 99.1 News Release FOR IMMEDIATE RELEASE Surendralal Karsanbhai Elected to Merck Board of Directors RAHWAY, N.J., Nov. 22, 2024 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that Surendralal L. “Lal” Karsanbhai, president and chief executive officer, Emerson Electric Co. (NYSE: EMR), will join Merck’s board of directors effective January 1, 2025. |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-6571 Merck & Co., Inc. (Exac |
|
| November 6, 2024 |
SC 13G/A 1 ff408710013ga1-evaxion.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Evaxion Biotech A/S (Name of Issuer) Ordinary Shares, DKK 1 nominal value per share (Title of Class of Securities) 29970R204** (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) |
|
| November 4, 2024 |
NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on November 15, 2024, pursuant to the provisions of Rule 12d2-2 (a). |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 31, 2024 (October 31, 2024) Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commissio |
|
| October 31, 2024 |
Exhibit 99.2 MERCK & CO., INC. CONSOLIDATED STATEMENT OF OPERATIONS - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a 2024 2023 % Change 1Q 2Q 3Q Sep YTD 1Q 2Q 3Q Sep YTD 4Q Full Year 3Q Sep YTD Sales $ 15,775 $ 16,112 $ 16,657 $ 48,544 $ 14,487 $ 15,035 $ 15,962 $ 45,485 $ 14,630 $ 60,115 4 % 7 % Costs, Expenses and Other Cost of sales 3,540 3,745 4,080 11,365 3,926 4,02 |
|
| October 31, 2024 |
Merck Announces Third-Quarter 2024 Financial Results Exhibit 99.1 News Release Merck Announces Third-Quarter 2024 Financial Results - Total Worldwide Sales Were $16.7 Billion, an Increase of 4% From Third Quarter 2023; Excluding the Impact of Foreign Exchange, Growth Was 7% o KEYTRUDA Sales Grew 17% to $7.4 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 21% o WINREVAIR Sales Were $149 Million; U.S. Launch of WINREVAIR Gaining Momentum |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-6571 Merck & Co., Inc. (Exact nam |
|
| July 30, 2024 |
Merck Announces Second-Quarter 2024 Financial Results Exhibit 99.1 News Release Merck Announces Second-Quarter 2024 Financial Results - Total Worldwide Sales Were $16.1 Billion, an Increase of 7% From Second Quarter 2023; Excluding the Impact of Foreign Exchange, Growth Was 11% - KEYTRUDA Sales Grew 16% to $7.3 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 21% - GAAP EPS Was $2.14; Non-GAAP EPS Was $2.28 - Successful Initial Launch of |
|
| July 30, 2024 |
Exhibit 99.2 MERCK & CO., INC. CONSOLIDATED STATEMENT OF OPERATIONS - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a 2024 2023 % Change 1Q 2Q June YTD 1Q 2Q June YTD 3Q 4Q Full Year 2Q June YTD Sales $ 15,775 $ 16,112 $ 31,887 $ 14,487 $ 15,035 $ 29,522 $ 15,962 $ 14,630 $ 60,115 7 % 8 % Costs, Expenses and Other Cost of sales 3,540 3,745 7,285 3,926 4,024 7,951 4,264 3, |
|
| July 30, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 30, 2024 (July 30, 2024) Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commission File |
|
| June 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS Pursuant to Section 15(d) of the Securities Exchange Act of 1934 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 1 |
|
| June 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS Pursuant to Section 15(d) of the Securities Exchange Act of 1934 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 1 |
|
| June 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS Pursuant to Section 15(d) of the Securities Exchange Act of 1934 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 1 |
|
| May 30, 2024 |
Exhibit 4.5 3.750% NOTES DUE 2054 MSD NETHERLANDS CAPITAL B.V. Officers’ Certificate Pursuant to the resolutions (collectively, the “Resolutions”) of the board of directors of MSD Netherlands Capital B.V., (the “Company”) duly adopted and dated May 13, 2024, which authorized the Company to issue and sell its debt securities and empowered each director of the Company (the “Officer”) to approve the |
|
| May 30, 2024 |
Exhibit 4.3 3.500% NOTES DUE 2037 MSD NETHERLANDS CAPITAL B.V. Officers’ Certificate Pursuant to the resolutions (collectively, the “Resolutions”) of the board of directors of MSD Netherlands Capital B.V., (the “Company”) duly adopted and dated May 13, 2024, which authorized the Company to issue and sell its debt securities and empowered each director of the Company (the “Officer”) to approve the |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation or organization) 22-1918501 (I.R.S Employer Identification No.) 126 |
|
| May 30, 2024 |
Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2024 Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey 1-6571 22-1918501 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 30, 2024 |
Exhibit 4.4 3.700% NOTES DUE 2044 MSD NETHERLANDS CAPITAL B.V. Officers’ Certificate Pursuant to the resolutions (collectively, the “Resolutions”) of the board of directors of MSD Netherlands Capital B.V., (the “Company”) duly adopted and dated May 13, 2024, which authorized the Company to issue and sell its debt securities and empowered each director of the Company (the “Officer”) to approve the |
|
| May 30, 2024 |
Exhibit 4.2 3.250% NOTES DUE 2032 MSD NETHERLANDS CAPITAL B.V. Officers’ Certificate Pursuant to the resolutions (collectively, the “Resolutions”) of the board of directors of MSD Netherlands Capital B.V., (the “Company”) duly adopted and dated May 13, 2024, which authorized the Company to issue and sell its debt securities and empowered each director of the Company (the “Officer”) to approve the |
|
| May 30, 2024 |
herlands Capital B.V., Merck & Co., Inc. and U.S. Bank Trust National Association Exhibit 4.1 MSD NETHERLANDS CAPITAL B.V. AND MERCK & CO., INC., as Parent Guarantor TO U.S. BANK TRUST NATIONAL ASSOCIATION, as Trustee Indenture Dated as of May 30, 2024 MSD NETHERLANDS CAPITAL B.V. MERCK & CO., INC. Certain Sections of this Indenture relating to Sections 310 through 318, inclusive, of the Trust Indenture Act of 1939 Trust Indenture Act Sections Indenture Sections § 310(a)(1) 609 |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD Specialized Disclosure Report Merck & Co., Inc. (Exact Name of Registrant as Specified in Its Charter) New Jersey 1-6571 (State or other jurisdiction of incorporation or organization) (Commission File Number) 126 East Lincoln Avenue, Rahway, NJ 07065 (Address of principal executive offices) (Zip Code) Jennifer Zachary |
|
| May 28, 2024 |
Exhibit 1.01 CONFLICT MINERALS REPORT FOR CALENDAR YEAR 2023 Part I: Introduction This document constitutes Merck & Co., Inc.’s Conflict Minerals Report (the “Report” or “CMR”) for the year ended December 31, 2023. We have prepared this Report and are issuing it in accordance with the requirements of Rule 13p-1 under the Securities Exchange Act of 1934, as amended, and in connection with Merck & C |
|
| May 20, 2024 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Merck & Co., Inc. MSD Netherlands Capital B.V. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate |
|
| May 20, 2024 |
Filed pursuant to Rule 424(b)(5) Filed pursuant to Rule 424(b)(5) Registration No. 333-278066 333-278066-01 Prospectus Supplement (To Prospectus dated May 14, 2024) €3,400,000,000 MSD Netherlands Capital B.V. (incorporated as a private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid) under the laws of the Netherlands with its official seat (statutaire zetel) in Haarlem, the Netherlands) Guaran |
|
| May 16, 2024 |
Issuer Free Writing Prospectus Filed under Rule 433 Registration Statement No. 333-278066 333-278066-01 Pricing Term Sheet MSD Netherlands Capital B.V. (the “Issuer”) May 16, 2024 3.250% Notes due 2032 3.500% Notes due 2037 3.700% Notes due 2044 3.750% Notes due 2054 Issuer: MSD Netherlands Capital B.V. Guarantor: Merck & Co., Inc., Rahway, N.J., USA Expected Ratings of the Notes:* A1 (positive) M |
|
| May 15, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Merck & Co., Inc. MSD Netherlands Capital B.V. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amo |
|
| May 15, 2024 |
Form of Underwriting Agreement for MSD Netherlands Capital B.V. debt securities. Exhibit 1(b) MSD Netherlands Capital B.V. Form of Debt Underwriting Agreement , 20 [Names and addresses of Underwriters] Ladies and Gentlemen: MSD Netherlands Capital B.V., a private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid) incorporated and existing under the laws of The Netherlands (the “Issuer”) registered with the Dutch Trade Register of the Dutch Ch |
|
| May 15, 2024 |
Exhibit 25(b) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) ☐ U.S. BANK TRUST NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 41-1973763 I.R.S. Employer |
|
| May 15, 2024 |
Exhibit 4(b) MSD NETHERLANDS CAPITAL B.V. AND MERCK & CO., INC., as Parent Guarantor TO U.S. BANK TRUST NATIONAL ASSOCIATION, as Trustee Indenture Dated as of [ ], 20[ ] MSD NETHERLANDS CAPITAL B.V. MERCK & CO., INC. Certain Sections of this Indenture relating to Sections 310 through 318, inclusive, of the Trust Indenture Act of 1939 Trust Indenture Act Sections Indenture Sections § 310(a)(1) 609 |
|
| May 15, 2024 |
As filed with the Securities and Exchange Commission on May 14, 2024 As filed with the Securities and Exchange Commission on May 14, 2024 Registration No. |
|
| May 15, 2024 |
Filed pursuant to Rule 424(b)(5) Filed pursuant to Rule 424(b)(5) Registration No. 333-278066 333-278066-01 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is unlawful or not |
|
| May 15, 2024 |
Exhibit 5(b) [Letterhead of Merck & Co., Inc.] May 14, 2024 Merck & Co., Inc. 126 East Lincoln Avenue Rahway, NJ 07065 MSD Netherlands Capital B.V. Waarderweg 39 2031 BN Haarlem, the Netherlands Re: Merck & Co., Inc. and MSD Netherlands Capital B.V. – Debt Securities and Guarantees Ladies and Gentlemen: I am the Executive Vice President and General Counsel of Merck & Co., Inc., a New Jersey corpor |
|
| May 15, 2024 |
Exhibit 23(a) CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in this Registration Statement on Form S-3 of Merck & Co. |
|
| May 15, 2024 |
Consent of Loyens & Loeff N.V. (contained in Exhibit 5(c) to this registration statement). Exhibit 5(c) POSTAL ADDRESS P.O. Box 71170 1008 BD AMSTERDAM OFFICE ADDRESS Parnassusweg 300 1081 LC AMSTERDAM The Netherlands INTERNET www.loyensloeff.com To: MSD Netherlands Capital B.V. Waarderweg 39 2031 BN Haarlem The Netherlands RE Dutch law legal opinion – MSD Netherlands Capital B.V. – SEC Registration REFERENCE 53996680 DATE 14 May 2024 1 INTRODUCTION We have acted as special counsel on c |
|
| May 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-6571 Merck & Co., Inc. (Exact na |
|
| April 25, 2024 |
Merck Announces First-Quarter 2024 Financial Results Exhibit 99.1 News Release Merck Announces First-Quarter 2024 Financial Results - Sales Reflect Continued Strong Growth in Oncology and Vaccines - Total Worldwide Sales Were $15.8 Billion, an Increase of 9% From First Quarter 2023; Excluding the Impact of Foreign Exchange, Growth Was 12% o KEYTRUDA Sales Grew 20% to $6.9 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 24% o GARDASIL/G |
|
| April 25, 2024 |
Exhibit 99.2 MERCK & CO., INC. CONSOLIDATED STATEMENT OF OPERATIONS - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a 2024 2023 % Change 1Q 1Q 2Q 3Q 4Q Full Year 1Q Sales $ 15,775 $ 14,487 $ 15,035 $ 15,962 $ 14,630 $ 60,115 9 % Costs, Expenses and Other Cost of sales 3,540 3,926 4,024 4,264 3,911 16,126 -10 % Selling, general and administrative 2,483 2,479 2,702 2,519 2, |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 25, 2024 (April 25, 2024) Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commission Fi |
|
| April 11, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2 |
|
| April 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy |
|
| April 11, 2024 |
As filed with the Securities and Exchange Commission on April 11, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| April 1, 2024 |
United States Securities and Exchange Commission Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION Pursuant to Rule 14a-103 Name of the Registrant: Merck & Co., Inc. Name of persons relying on exemption: Inspire Investing, LLC Address of persons relying on exemption: 3597 E Monarch Sky Ln, Suite 330, Meridian, ID 83646 As over 100 investors and financial professionals, serving thousands of clie |
|
| March 28, 2024 |
Vote Yes: Report on Respecting Workforce Civil Liberties NOTICE OF EXEMPT SOLICITATION SUBMITTED BY NON-MANAGEMENT U.S. Securities and Exchange Commission Washington, DC 20549 Notice of Exempt Solicitation under Rule 14a-103 Name of Registrant: Merck & Co., Inc. Name of person relying on exemption: Bowyer Research Address of person relying on exemption: P.O. Box 120, McKeesport, PA 15135 Vote Yes: Report on Respecting Workforce Civil Liberties Bowyer Re |
|
| March 19, 2024 |
Exhibit 25 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) U.S. BANK TRUST NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 41-1973763 I.R.S. Employer Ide |
|
| March 19, 2024 |
As filed with the Securities and Exchange Commission on March 19, 2024 Table of Contents As filed with the Securities and Exchange Commission on March 19, 2024 Registration No. |
|
| March 19, 2024 |
EX-23.A Exhibit 23(a) CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in this Registration Statement on Form S-3 of Merck & Co., Inc. of our report dated February 26, 2024 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in Merck & Co., Inc.’s Annual Report on Form 10- |
|
| March 19, 2024 |
As filed with the Securities and Exchange Commission on March 19, 2024 Table of Contents As filed with the Securities and Exchange Commission on March 19, 2024 Registration No. |
|
| March 19, 2024 |
EX-23.A Exhibit 23(a) CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in this Registration Statement on Form S-3 of Merck & Co., Inc. of our report dated February 26, 2024 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in Merck & Co., Inc.’s Annual Report on Form 10- |
|
| March 19, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Merck & Co., Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of |
|
| March 19, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Merck & Co., Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of |
|
| March 19, 2024 |
Form of Underwriting Agreement. Exhibit 1 MERCK & CO., INC. Form of Debt Underwriting Agreement , 20 [Names and addresses of Representatives] As Representatives of the several Underwriters named in Schedule I hereto Ladies and Gentlemen: Merck & Co., Inc., a New Jersey corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the firms named in Schedule I hereto (the “Unde |
|
| February 26, 2024 |
Exhibit 10.29 GLOBAL TERMS AND CONDITIONS 2023 PERFORMANCE SHARE UNIT GRANTS UNDER THE MERCK & CO., INC. 2019 INCENTIVE STOCK PLAN I.GENERAL. Merck & Co., Inc. (the “Company”) has granted to you the award of Performance Share Units (“PSUs”) specified in this document (“PSU Award”) pursuant to the Merck & Co., Inc. 2019 Incentive Stock Plan, including any sub-plan thereto for your country (the “Pla |
|
| February 26, 2024 |
Exhibit 10.25 GLOBAL TERMS AND CONDITIONS 2022 RESTRICTED STOCK UNIT GRANT FOR CHIRFI GUINDO UNDER THE MERCK & CO., INC. 2019 INCENTIVE STOCK PLAN I.GENERAL. Merck & Co., Inc. (the “Company”) has granted to you the Restricted Stock Unit (“RSU”) award specified in this document (“RSU Award”) pursuant to the Merck & Co., Inc. 2019 Incentive Stock Plan, including any sub-plan thereto for your country |
|
| February 26, 2024 |
Exhibit 10.27 GLOBAL TERMS AND CONDITIONS 2023 NON-QUALIFIED STOCK OPTION (NQSO) GRANTS UNDER THE MERCK & CO., INC. 2019 INCENTIVE STOCK PLAN I.GENERAL. Merck & Co., Inc. (the “Company”) has granted to you the stock option specified in this document pursuant to the Merck & Co., Inc. 2019 Incentive Stock Plan, including any sub-plan thereto for your country (the “Plan”). This stock option is subjec |
|
| February 26, 2024 |
2021 Performance Share Unit terms for grants under the Merck & Co., Inc. 2019 Incentive Stock Plan — Exhibit 10.23 2021 PERFORMANCE SHARE UNIT AWARD TERMS UNDER THE MERCK & CO., INC. 2019 STOCK INCENTIVE PLAN I.GENERAL. These Performance Share Units (“PSUs”) are granted under and subject to the following Award Terms and the Merck & Co., Inc. 2019 Stock Incentive Plan (the "Merck ISP"). The Company has announced its intention to spin-off (the “Spin-Off”) certain products into a new, independent, p |
|
| February 26, 2024 |
Exhibit 10.22 TERMS FOR 2020 RESTRICTED STOCK UNIT GRANTS UNDER THE MERCK & CO., 2019 INCENTIVE STOCK PLAN This is a summary of the terms applicable to the Restricted Stock Unit (RSU) Award specified in this document. Different terms may apply to any prior or future RSU Awards. Grant Type: RSU - Annual Grant Date: May 1, 2020 Vesting Dates Portion that Vests May 1, 2021 First: 33.333% May 1, 2022 |
|
| February 26, 2024 |
Terms for Restricted Stock Unit Grants under the Merck & Co., Inc. 2019 Incentive Stock Plan - Exhibit 10.24 TERMS FOR 2021 RETENTION RESTRICTED STOCK UNIT GRANTS UNDER THE MERCK & CO., 2019 INCENTIVE STOCK PLAN This is a summary of the terms applicable to the Restricted Stock Unit (RSU) Award specified in this document. Different terms may apply to any prior or future RSU Awards. Grant Type: RSU Grant Date: May 4, 2021 Vesting Date Portion that Vests May 4, 2024 100% Eligibility: Eligibili |
|
| February 26, 2024 |
Exhibit 10.30 June 8, 2022 Chirfi Guindo Dear Chirfi, It is my pleasure to offer you a position with Merck Sharp & Dohme LLC (“MSD” or the “Company”), a wholly-owned subsidiary of Merck & Co., Inc. (“Merck”), as its Chief Marketing Officer (the “Position”) on the terms and conditions set forth in this offer letter (“letter” or “offer letter”). We see ourselves as a company inspired to invent, and |
|
| February 26, 2024 |
Exhibit 10.8 TERMS FOR 2019 NON-QUALIFIED STOCK OPTION (NQSO) GRANTS UNDER THE MERCK & CO., INC. 2010 INCENTIVE STOCK PLAN This is a summary of the terms applicable to the stock option specified in this document. Different terms may apply to any prior or future stock option. Grant Type: NQSO – Annual Option Price: $77.62 Grant Date: May 3, 2019 Expiration Date: May 2, 2029 Vesting Date Portion tha |
|
| February 26, 2024 |
Exhibit 10.7 TERMS FOR 2017 NON-QUALIFIED STOCK OPTION (NQSO) GRANTS UNDER THE MERCK & CO., INC. 2010 INCENTIVE STOCK PLAN This is a summary of the terms applicable to the stock option specified in this document. Different terms may apply to any prior or future stock option. Grant Type: NQSO Option Price: $63.97 Grant Date: May 5, 2017 Expiration Date: May 4, 2027 Vesting Date Portion that Vests M |
|
| February 26, 2024 |
As filed with the Securities and Exchange Commission on February 26, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| February 26, 2024 |
Exhibit 24.1 POWER OF ATTORNEY Each of the undersigned does hereby appoint JENNIFER ZACHARY as his/her true and lawful attorney to execute on behalf of the undersigned (whether on behalf of the Company, or as an officer or director thereof, or by attesting the seal of the Company, or otherwise) the Annual Report on Form 10-K of Merck & Co., Inc. for the fiscal year ended December 31, 2023 under th |
|
| February 26, 2024 |
Exhibit 10.21 TERMS FOR 2020 NON-QUALIFIED STOCK OPTION (NQSO) GRANTS UNDER THE MERCK & CO., INC. 2019 INCENTIVE STOCK PLAN This is a summary of the terms applicable to the stock option specified in this document. Different terms may apply to any prior or future stock option. Grant Type: NQSO – Annual Option Price: $77.67 Grant Date: May 1, 2020 Expiration Date: April 31, 2030 Vesting Dates Portio |
|
| February 26, 2024 |
Exhibit 10.28 GLOBAL TERMS AND CONDITIONS 2022 PERFORMANCE SHARE UNIT GRANTS UNDER THE MERCK & CO., INC. 2019 INCENTIVE STOCK PLAN I.GENERAL. Merck & Co., Inc. (the “Company”) has granted to you the award of Performance Share Units (“PSUs”) specified in this document (“PSU Award”) pursuant to the Merck & Co., Inc. 2019 Incentive Stock Plan, including any sub-plan thereto for your country (the “Pla |
|
| February 26, 2024 |
Subsidiaries of Merck & Co., Inc. Exhibit 21 - MERCK & CO., INC. SUBSIDIARIES changes as 12/31/2023 The following is a list of subsidiaries of the Company, doing business under the name stated. Name Country or State of Incorporation 7728026 Canada Inc. Canada Abmaxis Inc. Delaware Acceleron Pharma Inc. Delaware Afferent Pharmaceuticals, Inc. Delaware Agrident GmbH Germany Agro Verhen B.V. Netherlands Allflex Argentina S.A. Argenti |
|
| February 26, 2024 |
Exhibit 10.13 MERCK & CO. INC. U.S. SEPARATION BENEFITS PLAN Amended and Restated as of January 1, 2019 MERCK & CO., INC., U.S. SEPARATION BENEFITS PLAN SECTION 1 PREAMBLE Merck Sharp & Dohme Corp. established the MSD Separation Benefits Plan (the "MSD Plan"), as amended from time to time, to provide benefits to eligible non-union employees whose employment with Merck Sharp & Dohme Corp. or a part |
|
| February 26, 2024 |
Certified Resolution of Board of Directors Exhibit 24.2 I, Kelly Grez, Corporate Secretary of Merck & Co., Inc. (the “Company”), a corporation duly organized and existing under the laws of the State of New Jersey, do hereby certify that the following is a true copy of a resolution adopted by unanimous written consent of the Board of Directors of the Company on February 24, 2023 in accordance with the provisions of the By-Laws of the Compan |
|
| February 26, 2024 |
Policy and Procedures for Recoupment of Incentive-Based Compensation Exhibit 97 Policy and Procedures for Recoupment of Incentive‐Based Compensation Policy The Compensation and Management Development Committee (the “Committee”) of the Board of Directors (the “Board”) has adopted this Incentive‐Based Compensation Recoupment Policy (the “Policy”) to comply with Section 10D of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), Rule 10D‐1 promulgated thereunder (“Rule 10D‐1”) and Paragraph 303A. |
|
| February 26, 2024 |
Exhibit 10.26 GLOBAL TERMS AND CONDITIONS 2022 SIGN-ON EQUITY GRANT OF PERFORMANCE SHARE UNITS FOR CHIRFI GUINDO UNDER THE MERCK & CO., INC. 2019 INCENTIVE STOCK PLAN I.GENERAL. Merck & Co., Inc. (the “Company”) has granted to you the award of Performance Share Units (“PSUs”) specified in this document (“PSU Award” or “Sign-On Equity”) pursuant to the Merck & Co., Inc. 2019 Incentive Stock Plan, i |
|
| February 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 20, 2024 (February 15, 2024) Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commiss |
|
| February 13, 2024 |
MRK / Merck & Co., Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0090-merckcoinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Merck & Co Inc Title of Class of Securities: Common Stock CUSIP Number: 58933Y105 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule |
|
| February 1, 2024 |
Exhibit 99.2 MERCK & CO., INC. CONSOLIDATED STATEMENT OF OPERATIONS - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a 2023 2022 % Change 1Q 2Q 3Q 4Q Full Year 1Q 2Q 3Q 4Q Full Year 4Q Full Year Sales $ 14,487 $ 15,035 $ 15,962 $ 14,630 $ 60,115 $ 15,901 $ 14,593 $ 14,959 $ 13,830 $ 59,283 6 % 1 % Costs, Expenses and Other Cost of sales 3,926 4,024 4,264 3,911 16,126 5,380 |
|
| February 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 1, 2024 (January 29, 2024) Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commissio |
|
| February 1, 2024 |
Merck Announces Fourth-Quarter and Full-Year 2023 Financial Results Exhibit 99.1 News Release Merck Announces Fourth-Quarter and Full-Year 2023 Financial Results - Fourth-Quarter and Full-Year Sales Reflect Sustained Growth Across Oncology and Vaccines - Fourth-Quarter Worldwide Sales Were $14.6 Billion, an Increase of 6% From Fourth Quarter 2022; Excluding LAGEVRIO, Growth Was 11%; Excluding LAGEVRIO and the Impact of Foreign Exchange, Growth Was 13% - Fourth-Qua |
|
| January 23, 2024 |
Joint Filing Agreement Pursuant to Rule 13d-1 Exhibit 99.1 Joint Filing Agreement Pursuant to Rule 13d-1 This agreement is made pursuant to Rule 13d-l(k)(1) under the Securities and Exchange Act of 1934, as amended (the “Act”) by and among the parties listed below, each referenced to herein as a “Joint Filer.” The Joint Filers agree that a statement of beneficial ownership as required by Sections 13(g) or 13(d) of the Act and the Rules thereu |
|
| January 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Evaxion Biotech A/S (Name of Issuer) Ordinary Shares, DKK 1 nominal value per share (Title of Class of Securities) 29970R204** (CUSIP Number) December 21, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| November 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 28, 2023 (November 21, 2023) Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commiss |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-6571 Merck & Co., Inc. (Exac |
|
| October 26, 2023 |
Merck Announces Third-Quarter 2023 Financial Results Exhibit 99.1 News Release Merck Announces Third-Quarter 2023 Financial Results - Sales Reflect Sustained Growth, Particularly in Oncology and Vaccines - Total Worldwide Sales Were $16.0 Billion, an Increase of 7% From Third Quarter 2022; Excluding LAGEVRIO, Growth Was 6%; Excluding LAGEVRIO and the Impact of Foreign Exchange, Growth Was 8% o KEYTRUDA Sales Grew 17% to $6.3 Billion; Excluding the I |
|
| October 26, 2023 |
Exhibit 99.2 MERCK & CO., INC. CONSOLIDATED STATEMENT OF OPERATIONS - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a 2023 2022 % Change 1Q 2Q 3Q Sep YTD 1Q 2Q 3Q Sep YTD 4Q Full Year 3Q Sep YTD Sales $ 14,487 $ 15,035 $ 15,962 $ 45,485 $ 15,901 $ 14,593 $ 14,959 $ 45,453 $ 13,830 $ 59,283 7 % – Costs, Expenses and Other Cost of sales 3,926 4,024 4,264 12,214 5,380 4,216 |
|
| October 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 26, 2023 Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commission File Number) 22-1 |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-6571 Merck & Co., Inc. (Exact nam |
|
| August 1, 2023 |
Exhibit 99.2 MERCK & CO., INC. CONSOLIDATED STATEMENT OF OPERATIONS - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a 2023 2022 % Change 1Q 2Q June YTD 1Q 2Q June YTD 3Q 4Q Full Year 2Q June YTD Sales $ 14,487 $ 15,035 $ 29,522 $ 15,901 $ 14,593 $ 30,494 $ 14,959 $ 13,830 $ 59,283 3 % -3 % Costs, Expenses and Other Cost of sales 3,926 4,024 7,951 5,380 4,216 9,596 3,934 3 |
|
| August 1, 2023 |
Merck Announces Second-Quarter 2023 Financial Results Exhibit 99.1 News Release Merck Announces Second-Quarter 2023 Financial Results - Sales Reflect Sustained Underlying Growth, Particularly in Oncology and Vaccines - Total Worldwide Sales Were $15.0 Billion, an Increase of 3% From Second Quarter 2022; Excluding LAGEVRIO, Growth Was 11%; Excluding LAGEVRIO and the Impact of Foreign Exchange, Growth Was 14% ○ KEYTRUDA Sales Grew 19% to $6.3 Billion; |
|
| August 1, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 1, 2023 Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commission File Number) 22-191 |
|
| June 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS Pursuant to Section 15(d) of the Securities Exchange Act of 1934 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 1 |
|
| June 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS Pursuant to Section 15(d) of the Securities Exchange Act of 1934 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 1 |
|
| June 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS Pursuant to Section 15(d) of the Securities Exchange Act of 1934 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 1 |
|
| May 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 26, 2023 (May 23, 2023) Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey 1-6571 22-1918501 (State or other jurisdiction of incorporation) (Commis |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD Specialized Disclosure Report Merck & Co., Inc. (Exact Name of Registrant as Specified in Its Charter) New Jersey 1-6571 (State or other jurisdiction of incorporation or organization) (Commission File Number) 126 East Lincoln Avenue, Rahway, NJ 07065 (Address of principal executive offices) (Zip Code) Jennifer Zachary |
|
| May 22, 2023 |
Exhibit 1.01 CONFLICT MINERALS REPORT FOR CALENDAR YEAR 2022 Part I: Introduction This document constitutes Merck & Co., Inc.’s Conflict Minerals Report (the “Report” or “CMR”) for the year ended December 31, 2022. We have prepared this Report and are issuing it in accordance with the requirements of Rule 13p-1 under the Securities Exchange Act of 1934, as amended, and in connection with Merck & C |
|
| May 18, 2023 |
United States Securities and Exchange Commission Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION Pursuant to Rule 14a-103 Name of the Registrant: Merck & Co., Inc. Name of persons relying on exemption: Boston Common Asset Management Address of persons relying on exemption: 200 State Street, 7th Floor Boston, MA 02109 Written materials are submitted pursuant to Rule 14a-6(g) (1) promulgated un |
|
| May 17, 2023 |
EX-4.5 Exhibit 4.5 5.000% NOTES DUE 2053 MERCK & CO., INC. Officers’ Certificate Pursuant to the resolutions (collectively, the “Resolutions”) of the Board of Directors of Merck & Co., Inc. (the “Company”) adopted at meetings duly called and held on March 23, 2021 and November 30, 2021 (at which meetings a quorum was present and acting throughout), which authorized the Company to issue and sell it |
|
| May 17, 2023 |
EX-4.6 Exhibit 4.6 5.150% NOTES DUE 2063 MERCK & CO., INC. Officers’ Certificate Pursuant to the resolutions (collectively, the “Resolutions”) of the Board of Directors of Merck & Co., Inc. (the “Company”) adopted at meetings duly called and held on March 23, 2021 and November 30, 2021 (at which meetings a quorum was present and acting throughout), which authorized the Company to issue and sell it |
|
| May 17, 2023 |
EX-4.3 Exhibit 4.3 4.500% NOTES DUE 2033 MERCK & CO., INC. Officers’ Certificate Pursuant to the resolutions (collectively, the “Resolutions”) of the Board of Directors of Merck & Co., Inc. (the “Company”) adopted at meetings duly called and held on March 23, 2021 and November 30, 2021 (at which meetings a quorum was present and acting throughout), which authorized the Company to issue and sell it |
|
| May 17, 2023 |
EX-4.4 Exhibit 4.4 4.900% NOTES DUE 2044 MERCK & CO., INC. Officers’ Certificate Pursuant to the resolutions (collectively, the “Resolutions”) of the Board of Directors of Merck & Co., Inc. (the “Company”) adopted at meetings duly called and held on March 23, 2021 and November 30, 2021 (at which meetings a quorum was present and acting throughout), which authorized the Company to issue and sell it |
|
| May 17, 2023 |
EX-4.2 Exhibit 4.2 4.300% NOTES DUE 2030 MERCK & CO., INC. Officers’ Certificate Pursuant to the resolutions (collectively, the “Resolutions”) of the Board of Directors of Merck & Co., Inc. (the “Company”) adopted at meetings duly called and held on March 23, 2021 and November 30, 2021 (at which meetings a quorum was present and acting throughout), which authorized the Company to issue and sell it |
|
| May 17, 2023 |
EX-4.1 Exhibit 4.1 4.050% NOTES DUE 2028 MERCK & CO., INC. Officers’ Certificate Pursuant to the resolutions (collectively, the “Resolutions”) of the Board of Directors of Merck & Co., Inc. (the “Company”) adopted at meetings duly called and held on March 23, 2021 and November 30, 2021 (at which meetings a quorum was present and acting throughout), which authorized the Company to issue and sell it |
|
| May 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 17, 2023 Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey 1-6571 22-1918501 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 10, 2023 |
424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-254703 Prospectus Supplement (To Prospectus dated March 25, 2021) $6,000,000,000 Merck & Co., Inc. $500,000,000 4.050% Notes due 2028 $750,000,000 4.300% Notes due 2030 $1,500,000,000 4.500% Notes due 2033 $750,000,000 4.900% Notes due 2044 $1,500,000,000 5.000% Notes due 2053 $1,000,000,000 5.150% Notes due 2063 We are |
|
| May 10, 2023 |
EX-FILING FEES 2 d358973dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table 424(b)(5) (Form Type) Merck & Co., Inc. (Exact Name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(1) |
|
| May 9, 2023 |
FWP Issuer Free Writing Prospectus Filed under Rule 433 Registration Statement No. |
|
| May 8, 2023 |
Subject to Completion, dated May 8, 2023 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-254703 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is unlaw |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-6571 Merck & Co., Inc. (Exact na |
|
| April 28, 2023 |
144 0001421339 XXXXXXXX LIVE 0000310158 MERCK & CO. INC. 001-06571 2000 Galloping Hill Road Kenilworth NJ 07033 908-740-4000 RICHARD ROBERT DELUCA Officer Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 38th Floor New York NY 10004 66163 7608844.24 2538592467 04/28/2023 NYSE Common 04/28/2023 Exercise of Options under an Issuer S-8 Registered Plan Issuer N 6616 |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 27, 2023 Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commission File Number) 22-191 |
|
| April 27, 2023 |
Exhibit 99.2 Proprietary MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a 2023 2022 % Change 1Q 1Q 2Q 3Q 4Q Full Year 1Q Sales $ 14,487 $ 15,901 $ 14,593 $ 14,959 $ 13,830 $ 59,283 -9 % Costs, Expenses and Other Cost of sales 3,926 5,380 4,216 3,934 3,881 17,411 -27 % Selling, general and administrative 2,479 2,323 2,512 |
|
| April 27, 2023 |
Merck Announces First-Quarter 2023 Financial Results Exhibit 99.1 News Release Merck Announces First-Quarter 2023 Financial Results - First Quarter 2023 Reflected Continued Strong Underlying Performance Across Key Growth Drivers, Particularly in Oncology and Vaccines - Total Worldwide Sales Were $14.5 Billion, a Decrease of 9% From First Quarter 2022; Excluding LAGEVRIO, Growth Was 11%; Excluding LAGEVRIO and the Impact of Foreign Exchange, Growth W |
|
| April 24, 2023 |
Notice of Exempt Solicitation Name of Registrant: Merck Name of Person Relying on Exempt Solicitation: Oxfam America Address of Person Relying on Exempt Solicitation: 77 North Washington Street, Suite 5-1, Boston, MA 02114 Written materials are submitted pursuant to Rule 14a-6(g)(1) promulgated under the Securities Exchange Act of 1934. |
|
| April 19, 2023 |
Notice of Exempt Solicitation Name of Registrant: Merck Name of Person Relying on Exempt Solicitation: Oxfam America Address of Person Relying on Exempt Solicitation: 77 North Washington Street, Suite 5-1, Boston, MA 02114 Written materials are submitted pursuant to Rule 14a-6(g)(1) promulgated under the Securities Exchange Act of 1934. |
|
| April 12, 2023 |
United States Securities and Exchange Commission Washington, DC 20549 NOTICE OF EXEMPT SOLICITATION United States Securities and Exchange Commission Washington, DC 20549 NOTICE OF EXEMPT SOLICITATION NAME OF REGISTRANT: Merck & Co. |
|
| April 3, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| April 3, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| February 24, 2023 |
Exhibit 10.36 GLOBAL TERMS AND CONDITIONS 2022 SIGN-ON EQUITY GRANT OF PERFORMANCE SHARE UNITS FOR CHIRFI GUINDO UNDER THE MERCK & CO., INC. 2019 INCENTIVE STOCK PLAN I.GENERAL. Merck & Co., Inc. (the “Company”) has granted to you the award of Performance Share Units (“PSUs”) specified in this document (“PSU Award” or “Sign-On Equity”) pursuant to the Merck & Co., Inc. 2019 Incentive Stock Plan, i |
|
| February 24, 2023 |
Exhibit 10.34 TERMS AND CONDITIONS 2022 EXECUTIVE CHAIRMAN RESTRICTED STOCK UNIT GRANT UNDER THE MERCK & CO., INC. 2019 INCENTIVE STOCK PLAN I.GENERAL. Merck & Co., Inc. (the “Company”) has granted to you the Restricted Stock Unit (“RSU”) award specified in this document (“RSU Award”) pursuant to the Merck & Co., Inc. 2019 Incentive Stock Plan (the “Plan”). This RSU Award is subject to the terms a |
|
| February 24, 2023 |
Exhibit 10.31 2021 PERFORMANCE SHARE UNIT AWARD TERMS UNDER THE MERCK & CO., INC. 2019 STOCK INCENTIVE PLAN I.GENERAL. These Performance Share Units (“PSUs”) are granted under and subject to the following Award Terms and the Merck & Co., Inc. 2019 Stock Incentive Plan (the "Merck ISP"). The Company has announced its intention to spin-off (the “Spin-Off”) certain products into a new, independent, p |
|
| February 24, 2023 |
Exhibit 10.13 MERCK & CO. INC. U.S. SEPARATION BENEFITS PLAN Amended and Restated as of January 1, 2019 MERCK & CO., INC., U.S. SEPARATION BENEFITS PLAN SECTION 1 PREAMBLE Merck Sharp & Dohme Corp. established the MSD Separation Benefits Plan (the "MSD Plan"), as amended from time to time, to provide benefits to eligible non-union employees whose employment with Merck Sharp & Dohme Corp. or a part |
|
| February 24, 2023 |
Exhibit 10.8 TERMS FOR 2019 NON-QUALIFIED STOCK OPTION (NQSO) GRANTS UNDER THE MERCK & CO., INC. 2010 INCENTIVE STOCK PLAN This is a summary of the terms applicable to the stock option specified in this document. Different terms may apply to any prior or future stock option. Grant Type: NQSO – Annual Option Price: $77.62 Grant Date: May 3, 2019 Expiration Date: May 2, 2029 Vesting Date Portion tha |
|
| February 24, 2023 |
Exhibit 10.7 TERMS FOR 2017 NON-QUALIFIED STOCK OPTION (NQSO) GRANTS UNDER THE MERCK & CO., INC. 2010 INCENTIVE STOCK PLAN This is a summary of the terms applicable to the stock option specified in this document. Different terms may apply to any prior or future stock option. Grant Type: NQSO Option Price: $63.97 Grant Date: May 5, 2017 Expiration Date: May 4, 2027 Vesting Date Portion that Vests M |
|
| February 24, 2023 |
Exhibit 24.1 POWER OF ATTORNEY Each of the undersigned does hereby appoint JENNIFER ZACHARY as his/her true and lawful attorney to execute on behalf of the undersigned (whether on behalf of the Company, or as an officer or director thereof, or by attesting the seal of the Company, or otherwise) the Annual Report on Form 10-K of Merck & Co., Inc. for the fiscal year ended December 31, 2022 under th |
|
| February 24, 2023 |
Exhibit 10.27 TERMS FOR 2020 RESTRICTED STOCK UNIT GRANTS UNDER THE MERCK & CO., 2019 INCENTIVE STOCK PLAN This is a summary of the terms applicable to the Restricted Stock Unit (RSU) Award specified in this document. Different terms may apply to any prior or future RSU Awards. Grant Type: RSU - Annual Grant Date: May 1, 2020 Vesting Dates Portion that Vests May 1, 2021 First: 33.333% May 1, 2022 |
|
| February 24, 2023 |
Subsidiaries of Merck & Co., Inc. Exhibit 21 - MERCK & CO., INC. SUBSIDIARIES changes as of 12/31/2022 The following is a list of subsidiaries of the Company, doing business under the name stated. Name Country or State of Incorporation 7728026 Canada Inc. Canada Abmaxis Inc. Delaware Acceleron Pharma Inc. Delaware Afferent Pharmaceuticals, Inc. Delaware Agrident GmbH Germany Agro Verhen B.V. Netherlands Aleis Pty Ltd Australia All |
|
| February 24, 2023 |
Exhibit 10.33 TERMS FOR 2021 RETENTION RESTRICTED STOCK UNIT GRANTS UNDER THE MERCK & CO., 2019 INCENTIVE STOCK PLAN This is a summary of the terms applicable to the Restricted Stock Unit (RSU) Award specified in this document. Different terms may apply to any prior or future RSU Awards. Grant Type: RSU Grant Date: May 4, 2021 Vesting Date Portion that Vests May 4, 2024 100% Eligibility: Eligibili |
|
| February 24, 2023 |
Certified Resolution of Board of Directors Exhibit 24.2 I, Kelly Grez, Corporate Secretary of Merck & Co., Inc. (the “Company”), a corporation duly organized and existing under the laws of the State of New Jersey, do hereby certify that the following is a true copy of a resolution adopted by unanimous written consent of the Board of Directors of the Company on February 24, 2023 in accordance with the provisions of the By-Laws of the Compan |
|
| February 24, 2023 |
Exhibit 10.35 GLOBAL TERMS AND CONDITIONS 2022 RESTRICTED STOCK UNIT GRANT FOR CHIRFI GUINDO UNDER THE MERCK & CO., INC. 2019 INCENTIVE STOCK PLAN I.GENERAL. Merck & Co., Inc. (the “Company”) has granted to you the Restricted Stock Unit (“RSU”) award specified in this document (“RSU Award”) pursuant to the Merck & Co., Inc. 2019 Incentive Stock Plan, including any sub-plan thereto for your country |
|
| February 24, 2023 |
Exhibit 10.30 TERMS FOR 2021 STOCK OPTION CEO GRANT UNDER THE MERCK & CO., INC. 2019 INCENTIVE STOCK PLAN This is a summary of the terms applicable to the stock option specified in this document. Different terms may apply to any prior or future stock option. Grant Type: CEO Grant Exercisable Date Portion Becoming Exercisable Option Price: $73.73 May 4, 2022 First: 33.333% Grant Date: May 4, 2021 M |
|
| February 24, 2023 |
Exhibit 10.28 2020 PERFORMANCE SHARE UNIT AWARD TERMS UNDER THE MERCK & CO., INC. 2019 STOCK INCENTIVE PLAN I.GENERAL. These Performance Share Units (“PSUs”) are granted under and subject to the following Award Terms and the Merck & Co., Inc. 2019 Stock Incentive Plan (the "Merck ISP"). The Company has announced its intention to spin-off (the “Spin-Off”) certain products into a new, yet-to-be-name |
|
| February 24, 2023 |
Exhibit 10.26 TERMS FOR 2020 STOCK OPTION CEO GRANT UNDER THE MERCK & CO., INC. 2019 INCENTIVE STOCK PLAN This is a summary of the terms applicable to the stock option specified in this document. Different terms may apply to any prior or future stock option. Grant Type: CEO Grant Exercisable Date Portion Becoming Exercisable Option Price: $75.36 May 1, 2021 First: 33.333% Grant Date: May 1, 2020 M |
|
| February 24, 2023 |
Exhibit 10.32 2021 CEO PERFORMANCE SHARE UNIT AWARD TERMS UNDER THE MERCK & CO., INC. 2019 STOCK INCENTIVE PLAN I.GENERAL. These Performance Share Units (“PSUs”) are granted under and subject to the following Award Terms and the Merck & Co., Inc. 2019 Stock Incentive Plan (the "Merck ISP"). The Company has announced its intention to spin-off (the “Spin-Off”) certain products into a new, independen |
|
| February 24, 2023 |
Exhibit 10.24 TERMS FOR 2019 RESTRICTED STOCK UNIT GRANTS UNDER THE MERCK & CO., INC. 2010 INCENTIVE STOCK PLAN This is a summary of the terms applicable to the Restricted Stock Unit (RSU) Award specified in this document. Different terms may apply to any prior or future RSU Awards. Grant Type: RSU Grant Date: May 3, 2019 Vesting Date Portion that Vests May 3, 2020 First: 33.333% May 3, 2021 Secon |
|
| February 24, 2023 |
Exhibit 10.29 2020 CEO PERFORMANCE SHARE UNIT AWARD TERMS UNDER THE MERCK & CO., INC. 2019 STOCK INCENTIVE PLAN I.GENERAL. These Performance Share Units (“PSUs”) are granted under and subject to the following Award Terms and the Merck & Co., Inc. 2019 Stock Incentive Plan (the "Merck ISP"). The Company has announced its intention to spin-off (the “Spin-Off”) certain products into a new, yet-to-be- |
|
| February 24, 2023 |
Offer Letter between Merck & Co., Inc. and Chirfi Guindo, dated June 8, 2022 - Filed herewith Exhibit 10.37 June 8, 2022 Chirfi Guindo Dear Chirfi, It is my pleasure to offer you a position with Merck Sharp & Dohme LLC (“MSD” or the “Company”), a wholly-owned subsidiary of Merck & Co., Inc. (“Merck”), as its Chief Marketing Officer (the “Position”) on the terms and conditions set forth in this offer letter (“letter” or “offer letter”). We see ourselves as a company inspired to invent, and |
|
| February 24, 2023 |
As filed with the Securities and Exchange Commission on February 24, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| February 24, 2023 |
Exhibit 10.23 TERMS FOR 2019 STOCK OPTION CEO GRANT UNDER THE MERCK & CO., INC. 2010 INCENTIVE STOCK PLAN This is a summary of the terms applicable to the stock option specified in this document. Different terms may apply to any prior or future stock option. Grant Type: CEO Grant Exercisable Date Portion Becoming Exercisable Option Price: $77.62 May 3, 2020 First: 33.333% Grant Date: May 3, 2019 M |
|
| February 24, 2023 |
Exhibit 10.25 TERMS FOR 2020 NON-QUALIFIED STOCK OPTION (NQSO) GRANTS UNDER THE MERCK & CO., INC. 2019 INCENTIVE STOCK PLAN This is a summary of the terms applicable to the stock option specified in this document. Different terms may apply to any prior or future stock option. Grant Type: NQSO – Annual Option Price: $77.67 Grant Date: May 1, 2020 Expiration Date: April 31, 2030 Vesting Dates Portio |
|
| February 9, 2023 |
MRK / Merck & Co., Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0082-merckcoinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Merck & Co. Inc. Title of Class of Securities: Common Stock CUSIP Number: 58933Y105 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rul |
|
| February 2, 2023 |
Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results Exhibit 99.1 News Release FOR IMMEDIATE RELEASE Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results - Fourth-Quarter and Full-Year 2022 Results Reflect Sustained Strong Revenue Growth - Fourth-Quarter 2022 Worldwide Sales Were $13.8 Billion, an Increase of 2% From Fourth Quarter 2021; Growth Excluding the Impact of Foreign Exchange Was 8% - Fourth-Quarter 2022 GAAP EPS From Continu |
|
| February 2, 2023 |
Exhibit 99.2 MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a 2022 2021 % Change 1Q 2Q 3Q 4Q Full Year 1Q 2Q 3Q 4Q Full Year 4Q Full Year Sales $ 15,901 $ 14,593 $ 14,959 $ 13,830 $ 59,283 $ 10,627 $ 11,402 $ 13,154 $ 13,521 $ 48,704 2 % 22 % Costs, Expenses and Other Cost of sales 5,380 4,216 3,934 3,881 17,411 3,199 3, |
|
| February 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 2, 2023 Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commission File Number) 22-1 |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-6571 Merck & Co., |
|
| October 27, 2022 |
Exhibit 99.3 News Release Media Contact: Johanna Herrmann Investor Contact: Peter Dannenbaum (617) 216-6029 (908) 740-1037 Robert M. Davis to Succeed Kenneth C. Frazier as Chairman of Merck Frazier to Retire After 30 years at Merck; Board of Directors Elects Davis as Company Chairman RAHWAY, N.J., October 26, 2022 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announ |
|
| October 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 27, 2022 (October 26, 2022) Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commissio |
|
| October 27, 2022 |
Exhibit 99.2 MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a 2022 2021 % Change 1Q 2Q 3Q Sep YTD 1Q 2Q 3Q Sep YTD 4Q Full Year 3Q Sep YTD Sales $ 15,901 $ 14,593 $ 14,959 $ 45,453 $ 10,627 $ 11,402 $ 13,154 $ 35,183 $ 13,521 $ 48,704 14 % 29 % Costs, Expenses and Other Cost of sales 5,380 4,216 3,934 13,530 3,199 3,104 |
|
| October 27, 2022 |
Merck Announces Third-Quarter 2022 Financial Results Exhibit 99.1 News Release FOR IMMEDIATE RELEASE Merck Announces Third-Quarter 2022 Financial Results · Third-Quarter Results Reflect Sustained Strong Business Momentum Across Key Growth Drivers as Well as Investment and Progress in the Pipeline · Third-Quarter 2022 Worldwide Sales Were $15.0 Billion, an Increase of 14% From Third-Quarter 2021; LAGEVRIO Sales Were $436 Million; Growth Excluding LAG |
|
| August 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-6571 Merck & Co., Inc. |
|
| July 28, 2022 |
Merck Announces Second-Quarter 2022 Financial Results Exhibit 99.1 News Release Merck Announces Second-Quarter 2022 Financial Results - Merck Delivers Robust Sales Growth and Important Clinical Advancements in Second Quarter - Second-Quarter 2022 Worldwide Sales Were $14.6 Billion, an Increase of 28% From Second Quarter 2021; LAGEVRIO Sales Were $1.2 Billion, Growth Excluding LAGEVRIO Was 18%; Growth Excluding LAGEVRIO and the Impact From Foreign Exc |
|
| July 28, 2022 |
Exhibit 99.2 MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a 2022 2021 % Change 1Q 2Q June YTD 1Q 2Q June YTD 3Q 4Q Full Year 2Q June YTD Sales $ 15,901 $ 14,593 $ 30,494 $ 10,627 $ 11,402 $ 22,029 $ 13,154 $ 13,521 $ 48,704 28 % 38 % Costs, Expenses and Other Cost of sales 5,380 4,216 9,596 3,199 3,104 6,303 3,450 3,87 |
|
| July 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 28, 2022 Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commission File Number) 22-1918 |
|
| June 15, 2022 |
11-K 1 a11-kmsdemployeestockpurc.htm FORM 11-K: MSD EMPLOYEE STOCK PURCHASE AND SAVINGS PLAN UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS Pursuant to Section 15(d) of the Securities Exchange Act of 1934 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF |
|
| June 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS Pursuant to Section 15(d) of the Securities Exchange Act of 1934 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 1 |
|
| June 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS Pursuant to Section 15(d) of the Securities Exchange Act of 1934 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 1 |
|
| May 26, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 26, 2022 (May 24, 2022) Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey 1-6571 22-1918501 (State or other jurisdiction (Commission (I.R.S Employ |
|
| May 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD Specialized Disclosure Report Merck & Co., Inc. (Exact Name of Registrant as Specified in Its Charter) New Jersey 1-6571 (State or other jurisdiction of incorporation or organization) (Commission File Number) 126 East Lincoln Avenue, Rahway, NJ 07065 (Address of principal executive offices) (Zip Code) Jennifer Zachary |
|
| May 20, 2022 |
Exhibit 1.01 CONFLICT MINERALS REPORT FOR CALENDAR YEAR 2021 Part I: Introduction This document constitutes Merck & Co., Inc.?s Conflict Minerals Report (the ?Report? or ?CMR?) for the year ended December 31, 2021. We have prepared this Report and are issuing it in accordance with the requirements of Rule 13p-1 under the Securities Exchange Act of 1934, as amended, and in connection with Merck & C |
|
| May 13, 2022 |
Notice of Exempt Solicitation NAME OF REGISTRANT: Merck NAME OF PERSON RELYING ON EXEMPTION: Oxfam America ADDRESS OF PERSON RELYING ON EXEMPTION: 226 Causeway Street, Boston, MA 02114 Written materials are submitted pursuant to Rule 14(a)-6(g)(1) promulgated under the Securities and Exchange Act of 1934. |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-6571 Merck & Co., Inc |
|
| April 28, 2022 |
Exhibit 99.2 MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a 2022 2021 % Change 1Q 1Q 2Q 3Q 4Q Full Year 1Q Sales $ 15,901 $ 10,627 $ 11,402 $ 13,154 $ 13,521 $ 48,704 50 % Costs, Expenses and Other Cost of sales 5,380 3,199 3,104 3,450 3,873 13,626 68 % Selling, general and administrative 2,323 2,187 2,281 2,336 2,830 |
|
| April 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 28, 2022 Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commission File Number) 22-191 |
|
| April 28, 2022 |
Merck Announces First-Quarter 2022 Financial Results Exhibit 99.1 News Release Media Contacts: Melissa Moody Investor Contacts: Peter Dannenbaum (215) 407-3536 (908) 740-1037 Johanna Herrmann (617) 216-6029 Steven Graziano (908) 740-6582 Merck Announces First-Quarter 2022 Financial Results - First-Quarter 2022 Results Reflect Sustained Strong Business Momentum, With Robust Top- and Bottom-Line Growth - First-Quarter 2022 Worldwide Sales From Continu |
|
| April 21, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 20, 2022 Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commission File Number) 22-191 |
|
| April 21, 2022 |
2021 and 2020 Historical Non-GAAP Financial Information Recast to Reflect Reporting Changes Exhibit 99.1 MERCK & CO., INC. 2021 QUARTERLY AND ANNUAL GAAP TO NON-GAAP RECONCILIATIONS - CONTINUING OPERATIONS (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) In 2022, the Company will be changing the treatment of certain items for purposes of its non-GAAP reporting. Historically, Merck?s non-GAAP results excluded expenses for upfront and milestone payments related to collaborations |
|
| April 4, 2022 | ||
| April 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 4, 2022 |
DEF 14A 1 d154286ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as |
|
| March 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 25, 2022 (March 22, 2022) Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey 1-6571 22-1918501 (State or other jurisdiction (Commission (I.R.S Em |
|
| March 25, 2022 |
Exhibit 3.1 By-Laws OF MERCK & CO., INC. Effective as of March 22, 2022 By-Laws OF Merck & Co., Inc. A R T I C L E I. SHAREHOLDERS. SECTION 1. Annual Meeting. A meeting of the shareholders of Merck & Co., Inc. (hereinafter referred to as the ?Company?) shall be held at such places as may from time to time be designated by the Board of Directors and stated in the notice of the meeting for the purpo |
|
| February 25, 2022 |
As filed with the Securities and Exchange Commission on February 25, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| February 25, 2022 |
Exhibit 10.25 GLOBAL TERMS AND CONDITIONS 2022 RESTRICTED STOCK UNIT GRANTS UNDER THE MERCK & CO., INC. 2019 INCENTIVE STOCK PLAN Grant Type: RSU - Annual Grant Date: May 3, 2022 Vesting Dates Portion that Vests May 3, 2023 First: 33.333% May 3, 2024 Second: 33.333% May 3, 2025 Third: Balance I.GENERAL. Merck & Co., Inc. (the ?Company?) has granted to you the Restricted Stock Unit (?RSU?) award sp |
|
| February 25, 2022 |
Exhibit 24.1 POWER OF ATTORNEY Each of the undersigned does hereby appoint JENNIFER ZACHARY as his/her true and lawful attorney to execute on behalf of the undersigned (whether on behalf of the Company, or as an officer or director thereof, or by attesting the seal of the Company, or otherwise) the Annual Report on Form 10-K of Merck & Co., Inc. for the fiscal year ended December 31, 2021 under th |
|
| February 25, 2022 |
Exhibit 10.24 GLOBAL TERMS AND CONDITIONS 2022 NON-QUALIFIED STOCK OPTION (NQSO) GRANTS UNDER THE MERCK & CO., INC. 2019 INCENTIVE STOCK PLAN Grant Type: NQSO ? Annual Option Price: $XX.XX Grant Date: May 3, 2022 Expiration Date: May 2, 2032 Vesting Dates Portion that Vests May 3, 2023 First: 33.333% May 3, 2024 Second: 33.333% May 3, 2025 Third: Balance I.GENERAL Merck & Co., Inc. (the ?Company?) |
|
| February 25, 2022 |
Certified Resolution of Board of Directors Exhibit 24.2 I, Kelly Grez, Deputy Corporate Secretary of Merck & Co., Inc. (the ?Company?), a corporation duly organized and existing under the laws of the State of New Jersey, do hereby certify that the following is a true copy of a resolution adopted by unanimous written consent of the Board of Directors of the Company on February 25, 2022 in accordance with the provisions of the By-Laws of the |
|
| February 25, 2022 |
Subsidiaries of Merck & Co., Inc. EXHIBIT 21 MERCK & CO., INC. SUBSIDIARIES as of 12/31/2021 The following is a list of subsidiaries of the Company, doing business under the name stated. Name Country or State of Incorporation 7728026 Canada Inc. Canada Abmaxis Inc. Delaware Acceleron Holding Ltd. Bermuda Acceleron Pharma Canada Inc. Canada (BC) Acceleron Pharma Germany GmbH Germany Acceleron Pharma Inc. Delaware Acceleron Pharma N |
|
| February 25, 2022 |
Exhibit 10.17 MERCK & CO., INC. PLAN FOR DEFERRED PAYMENT OF DIRECTORS' COMPENSATION (Effective as Amended and Restated January 1, 2022) TABLE OF CONTENTS Page Article I Purpose 1 Article II Election of Deferral, Investment Alternatives and Distribution Schedule 1 Article III Valuation of Deferred Amounts 3 Article IV Redesignation Within a Deferral Account 5 Article V Payment of Deferred Amounts |
|
| February 9, 2022 |
MRK / Merck & Co., Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0070-merckcoinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Merck & Co. Inc. Title of Class of Securities: Common Stock CUSIP Number: 58933Y105 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rul |
|
| February 3, 2022 |
Exhibit 99.2 MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a 2021 2020 % Change 1Q 2Q 3Q 4Q Full Year 1Q 2Q 3Q 4Q Full Year 4Q Full Year Sales $ 10,627 $ 11,402 $ 13,154 $ 13,521 $ 48,704 $ 10,288 $ 9,353 $ 10,929 $ 10,948 $ 41,518 24 % 17 % Costs, Expenses and Other Cost of sales 3,199 3,104 3,450 3,873 13,626 2,829 2, |
|
| February 3, 2022 |
Merck Announces Fourth-Quarter and Full-Year 2021 Financial Results Exhibit 99.1 News Release Media Contacts: Melissa Moody (215) 407-3536 Investor Contacts: Peter Dannenbaum (908) 740-1037 Johanna Herrmann (617) 216-6029 Steven Graziano (908) 740-6582 Merck Announces Fourth-Quarter and Full-Year 2021 Financial Results ? Fourth-Quarter and Full-Year Results Reflect Continued Strong Business Momentum and Operational Strength ? Fourth-Quarter 2021 Worldwide Sales Fr |
|
| February 3, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 3, 2022 Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commission File Number) 22-1 |
|
| February 2, 2022 |
Joint Filing Agreement Pursuant to Rule 13d-1 EXHIBIT 99.1 Joint Filing Agreement Pursuant to Rule 13d-1 This agreement is made pursuant to Rule 13d-l(k)(1) under the Securities and Exchange Act of 1934, as amended (the ?Act?) by and among the parties listed below, each referenced to herein as a ?Joint Filer.? The Joint Filers agree that a statement of beneficial ownership as required by Sections 13(g) or 13(d) of the Act and the Rules thereu |
|
| February 2, 2022 |
LBPS / 4D pharma plc / Merck & Co., Inc. - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* 4D pharma plc Ordinary Shares, nominal value ?0.0025 per share (Title of Class of Securities) 35085K109** (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| December 10, 2021 |
Exhibit 4.2 EXECUTION VERSION 1.900% NOTES DUE 2028 MERCK & CO., INC. Officers? Certificate Pursuant to the resolutions (collectively, the ?Resolutions?) of the Board of Directors of Merck & Co., Inc. (the ?Company?) adopted at meetings duly called and held on March 23, 2021 and November 30, 2021 (at which meetings a quorum was present and acting throughout), which authorized the Company to issue |
|
| December 10, 2021 |
Exhibit 4.4 EXECUTION VERSION 2.750% NOTES DUE 2051 MERCK & CO., INC. Officers? Certificate Pursuant to the resolutions (collectively, the ?Resolutions?) of the Board of Directors of Merck & Co., Inc. (the ?Company?) adopted at meetings duly called and held on March 23, 2021 and November 30, 2021 (at which meetings a quorum was present and acting throughout), which authorized the Company to issue |
|
| December 10, 2021 |
Exhibit 4.1 EXECUTION VERSION 1.700% NOTES DUE 2027 MERCK & CO., INC. Officers? Certificate Pursuant to the resolutions (collectively, the ?Resolutions?) of the Board of Directors of Merck & Co., Inc. (the ?Company?) adopted at meetings duly called and held on March 23, 2021 and November 30, 2021 (at which meetings a quorum was present and acting throughout), which authorized the Company to issue |
|
| December 10, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 10, 2021 Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey 1-6571 22-1918501 (State or other jurisdiction of incorporation) (Commission File |
|
| December 10, 2021 |
Exhibit 4.3 EXECUTION VERSION 2.150% NOTES DUE 2031 MERCK & CO., INC. Officers? Certificate Pursuant to the resolutions (collectively, the ?Resolutions?) of the Board of Directors of Merck & Co., Inc. (the ?Company?) adopted at meetings duly called and held on March 23, 2021 and November 30, 2021 (at which meetings a quorum was present and acting throughout), which authorized the Company to issue |
|
| December 10, 2021 |
Exhibit 4.5 EXECUTION VERSION 2.900% NOTES DUE 2061 MERCK & CO., INC. Officers? Certificate Pursuant to the resolutions (collectively, the ?Resolutions?) of the Board of Directors of Merck & Co., Inc. (the ?Company?) adopted at meetings duly called and held on March 23, 2021 and November 30, 2021 (at which meetings a quorum was present and acting throughout), which authorized the Company to issue |
|
| December 9, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-254703 CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be registered Maximum offering price per security Maximum aggregate offering price Amount of registration fee (1) 1.700% Notes due 2027 $1,500,000,000 99.958% $1,499,370,000 $138,991.60 1.900% Notes due 2028 $1,000,000,000 99.82 |
|
| December 8, 2021 |
FWP 1 d253432dfwp.htm FWP Issuer Free Writing Prospectus Filed under Rule 433 Registration Statement No. 333-254703 Pricing Term Sheet Merck & Co., Inc. December 7, 2021 1.700% Notes due 2027 1.900% Notes due 2028 2.150% Notes due 2031 2.750% Notes due 2051 2.900% Notes due 2061 Unless otherwise indicated, terms used but not defined herein have the meanings assigned to such terms in the preliminar |
|
| December 7, 2021 |
Subject to Completion, dated December 7, 2021 424B5 1 d128376d424b5.htm 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-254703 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities in any jurisdiction where |
|
| November 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-6571 Merck & Co., |
|
| October 28, 2021 |
Exhibit 99.2 MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a 2021 2020 % Change 1Q 2Q 3Q Sep YTD 1Q 2Q 3Q Sep YTD 4Q Full Year 3Q Sep YTD Sales $ 10,627 $ 11,402 $ 13,154 $ 35,183 $ 10,288 $ 9,353 $ 10,929 $ 30,570 $ 10,948 $ 41,518 20% 15% Costs, Expenses and Other Cost of sales 3,199 3,104 3,450 9,752 2,829 2,747 3,01 |
|
| October 28, 2021 |
Merck Announces Third-Quarter 2021 Financial Results Exhibit 99.1 FOR IMMEDIATE RELEASE Media Contacts: Patrick Ryan Investor Contacts: Peter Dannenbaum (973) 275-7075 (908) 740-1037 Melissa Moody Raychel Kruper (215) 407-3536 (908) 740-2107 Merck Announces Third-Quarter 2021 Financial Results ? Results Demonstrate Strong Momentum Across Business ? Third-Quarter 2021 Worldwide Sales Were $13.2 Billion, 20% Above Third-Quarter 2020; Excluding the Imp |
|
| October 28, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 28, 2021 Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commission File Number) 22-1 |
|
| October 15, 2021 |
EX-99.25 2 ruleprovisionnotice.htm NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on October 26, 2021, pursuant to the provisions of Rule 12d2-2 (a). [ X ] 17 CFR 240.12d |
|
| August 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 20, 2021 (August 19, 2021) Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey 1-6571 22-1918501 (State or other jurisdiction of incorporation) ( |
|
| August 20, 2021 |
Leslie A. Brun Resigns from Merck Board of Directors Exhibit 99.1 News Release FOR IMMEDIATE RELEASE Media Contacts: Patrick Ryan Investor Contacts: Peter Dannenbaum (973) 275-7075 (908) 740-1037 Melissa Moody (215) 407-3536 Raychel Kruper (908) 740-2107 Leslie A. Brun Resigns from Merck Board of Directors KENILWORTH, N.J., Aug. 20, 2021 ? Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Leslie A. Brun, its |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-6571 Merck & Co., Inc. |
|
| July 29, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 29, 2021 Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commission File Number) 22-1918 |
|
| July 29, 2021 |
Merck Announces Second-Quarter 2021 Financial Results Exhibit 99.1 FOR IMMEDIATE RELEASE Media Contacts: Patrick Ryan Investor Contacts: Peter Dannenbaum (973) 275-7075 (908) 740-1037 Melissa Moody (215) 407-3536 Raychel Kruper (908) 740-2107 Merck Announces Second-Quarter 2021 Financial Results ? Second-Quarter 2021 Worldwide Sales from Continuing Operations (Excluding Organon) Were $11.4 Billion, 22% Above Second-Quarter 2020; Excluding the Impact |
|
| July 29, 2021 |
Exhibit 99.2 MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a 2021 2020 % Change 1Q 2Q June YTD 1Q 2Q June YTD 3Q 4Q Full Year 2Q June YTD Sales $ 10,627 $ 11,402 $ 22,029 $ 10,288 $ 9,353 $ 19,641 $ 10,929 $ 10,948 $ 41,518 22 % 12 % Costs, Expenses and Other Cost of sales 3,199 3,104 6,303 2,829 2,747 5,576 3,013 5,029 |
|
| June 21, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 21, 2021 Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commission File Number) 22-1918 |
|
| June 21, 2021 |
Exhibit 99.1 MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) On June 2, 2021, Merck completed the spinoff of products from its women?s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon & Co. (Organon) through a distribution of Organon?s publicly traded stock to c |
|
| June 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS Pursuant to Section 15(d) of the Securities Exchange Act of 1934 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 1 |
|
| June 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS Pursuant to Section 15(d) of the Securities Exchange Act of 1934 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 1 |
|
| June 16, 2021 |
11-K 1 a11-kmerckussavingsplanye.htm FORM 11-K: MERCK US SAVINGS PLAN UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS Pursuant to Section 15(d) of the Securities Exchange Act of 1934 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal yea |
|
| June 3, 2021 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 2, 2021 Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey 1-6571 22-1918501 (State or other jurisdiction of incorporation) (Commission File Numb |
